Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The market for sodium-glucose cotransporter 2 (SGLT2) inhibitors has experienced significant expansion recently, with projections indicating continued robust growth. This sector is anticipated to increase from a value of $10.96 billion in 2025 to $11.87 billion by the following year, exhibiting a compound annual growth rate of 8.3%. Historical drivers behind this market’s ascent include the increasing prevalence of type 2 diabetes, persistent demands for improved glycemic management, positive outcomes from clinical research, heightened physician understanding of these therapies, and the granting of regulatory endorsements.
The market for sodium-glucose cotransporter 2 (SGLT2) inhibitors is poised for substantial expansion, projected to reach $16.35 billion by 2030, reflecting a compound annual growth rate of 8.3%. This anticipated surge is fueled by an increasing awareness of their cardio-renal advantages, a growing demographic of elderly individuals with diabetes, broader insurance coverage, the introduction of novel pharmaceutical products, and deeper inroads into developing economies. Key developments anticipated during this forecast period encompass the utilization of these inhibitors beyond their primary indication of diabetes, a greater embrace of combination treatment strategies, an upswing in their application for heart failure, enhanced safety profiles, and elevated inclusion within clinical guidelines.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Industry Drivers: What Is Driving Revenue Growth?
The expanding incidence of diabetes is anticipated to be a primary catalyst for the advancement of the sodium glucose cotransporter 2 (SGLT2) inhibitor market. Diabetes, a collection of metabolic conditions marked by elevated blood glucose, stems from issues with insulin production, its effectiveness, or both. This surge in diabetes cases is linked to increased urbanization, heightened stress levels, environmental contaminants, and limited access to medical care. SGLT2 inhibitors are employed in diabetes management to decrease blood sugar by inhibiting the reabsorption of glucose in the kidneys, thus facilitating its elimination through urine, and additionally provide advantages for both cardiac and kidney health, positioning them as a significant therapeutic choice for controlling diabetes and its associated health issues. Illustratively, OHID data from March 2025 indicated that the proportion of adults in England aged 17 and above diagnosed with type 2 diabetes by general practitioners stood at 7.0% in March 2024, showing an increase from the 6.8% recorded in March 2023. Consequently, the growing prevalence of diabetes directly fuels the expansion of the SGLT2 inhibitor market.
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Segment Analysis Highlighting Growth Areas
The sodium glucose cotransporter 2 (sglt2) inhibitors market covered in this report is segmented –
1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat
2) By Route Of Administration: Oral Route, Other Route Of Administration
3) By End User: Hospitals, Homecare Settings, Clinics
Subsegments:
1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana
2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance
3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga
4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure
#Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Growth Trends: What Is Influencing The Future Outlook?
In the realm of SGLT2 inhibitors, leading entities are concentrating their efforts on pioneering dual inhibitor therapies aimed at optimizing patient results and blood glucose regulation. These dual inhibitor approaches involve simultaneously engaging two distinct sodium-glucose cotransporters, SGLT1 and SGLT2, thereby amplifying their effectiveness in addressing conditions like cardiac insufficiency and diabetes. A notable development occurred in May 2023 when Lexicon Pharmaceuticals Inc., a biopharmaceutical firm based in the United States, secured FDA clearance for sotagliflozin, a therapeutic agent for heart failure. This groundbreaking dual inhibitor, targeting both SGLT1 and SGLT2, is formulated as a once-daily oral medication intended to decrease cardiovascular mortality, hospitalizations due to heart failure, and unscheduled visits for heart failure management among adults diagnosed with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk indicators. Its therapeutic advantages stem from a diminished reabsorption of glucose and sodium by the kidneys, resulting in a reduction of both preload and afterload, coupled with diminished sympathetic nervous system activity.
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the sodium glucose cotransporter 2 (sglt2) inhibitors market are Johnson & Johnson Inc., Merck & Co Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma Inc, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co Ltd, Taisho Pharmaceutical Holdings Co Ltd, Lupin Limited, Glenmark Pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co Ltd, Kotobuki Pharmaceutical Co Ltd, Lexicon Pharmaceuticals Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Hanmi Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, Mitsubishi Tanabe Pharma Corporation
Access The Complete Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report:
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Largest Region: Which Geography Holds The Highest Market Share?
North Americawas the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (sglt2) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
